-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on NeoGenomics, Maintains $14 Price Target

Benzinga·01/12/2026 15:32:53
Listen to the news
Needham analyst Mike Matson reiterates NeoGenomics (NASDAQ:NEO) with a Buy and maintains $14 price target.